Search results
Alumis cuts IPO size, but nets $250M for immune drug work
BioPharma Dive· 3 days agoAlumis’ public offering comes during an uptick in interest in immune drugs. Still, the company sold...
Alumis’ public offering comes during an uptick in interest in immune drugs. Still, the company sold...